• Explore /
  • Poster
  • / A phase II study of TAS-102 (FTD/TPI) in combination with ramucirumab (RAM) in advanced, refractory gastric (GC) or gastroesophageal junction (GEJ) adenocarcinomas (GEAs).

A phase II study of TAS-102 (FTD/TPI) in combination with ramucirumab (RAM) in advanced, refractory gastric (GC) or gastroesophageal junction (GEJ) adenocarcinomas (GEAs).

Abstract Poster

Authors

null

Rutika Mehta

H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

Rutika Mehta , Richard D. Kim , Maria E Martinez Jimenez , Kirsten Blue , Trenton Avriett , Emily Kelbert , Kara Miller , Christopher Ray , Tiffany Valone , Woojoo Lee , Youngchul Kim , Dae Won Kim

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03686488

DOI

10.1200/JCO.2022.40.4_suppl.302

Abstract #

302

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Rutika Mehta

First Author: Thorsten Oliver Goetze

First Author: Timothy Jay Price

First Author: Anwaar Saeed